Capital Flows and Market Restructuring in Cancer and Immunotherapy

In the first half of 2026, the global biotech venture capital (VC) market saw an even greater concentration of funding in the areas of cancer and autoimmune disease treatments. Of the total investment of over $9 billion from 26 active investment firms, more than 40%, or $3.9 billion, was concentrated in these two areas. Specifically, $2.1 billion flowed into the autoimmune disease treatment sector, reflecting the market's high expectations for this area. This indicates that capital is being prioritized for chronic diseases with proven commercial viability and clear unmet medical needs, rather than short-term trend-driven diseases.

Large-Scale Funding for Leading Pipeline Assets and Technological Differentiation

Investment is increasingly focused on the differentiated technologies that determine the survival and growth of startups. Specifically, Isomorphic Labs, an AI-based drug discovery company, secured a massive $2.1 billion in funding, and NewLimit, a longevity startup, raised $435 million. Additionally, Parabilis Medicines (NASDAQ: PBLS), which is developing zolucatetide, a targeted cancer drug that inhibits the binding of beta-catenin and TCF, completed a Series F funding round of $305 million in January, just before its initial public offering (IPO).

Beeline Medicines, a spin-out from Bristol Myers Squibb (NYSE: BMY), also successfully raised $426.3 million in Series A funding to accelerate clinical trials for afimetoran, a lupus treatment candidate.

Big Pharma's Active M&A Strategy and Pipeline Acquisition

Global pharmaceutical giants are actively acquiring promising assets in early clinical stages to prepare for the upcoming patent cliff. Gilead Sciences (NASDAQ: GILD) acquired Ouro Medicines, which holds gamgertamig, a bispecific T-cell engager (BCMAxCD3 TCE), for a total of $2.175 billion ($1.675 billion upfront and $500 million in milestones). Biogen (NASDAQ: BIIB) also agreed to acquire RayThera, which develops small-molecule anti-inflammatory therapies, for up to $1 billion to strengthen its autoimmune disease pipeline. Meanwhile, Candid Therapeutics canceled its reverse merger with Rallybio and was acquired by UCB for a total of $2.2 billion ($2 billion upfront and $200 million in milestones), solidifying its 'immune reset' strategy.

IPO Market Activation and Successful Listing of Companies

The strong performance of cancer and immunology companies is also directly linked to the success rate of IPOs in the public market, expanding the exit opportunities for venture capital. In the first half of 2026, six of the 13 biotech companies that went public were developing cancer or autoimmune disease treatments. Notably, Parabilis Medicines successfully debuted on the Nasdaq in June, raising $670 million in the largest offering of the year. This successful listing is a positive sign, indicating that novel drug candidates with late-stage clinical data can be fairly valued in the market.

Mid- to Long-Term Market Outlook and Implications for Investors

This investment trend provides a lesson that even if the timeline for new drug development is long, pipelines with proven clinical efficacy and market potential will survive. Ben Zercher, Senior Analyst at PitchBook, analyzed that unlike obesity or metabolic diseases, the cancer and immunology fields have long-term growth potential that is not subject to trends. Ultimately, the demand from big pharma to secure new modalities in preparation for upcoming patent expirations will inevitably continue. Therefore, investors need to continue to pay attention to private startups that demonstrate excellent safety and strong efficacy data in Phase 1/2 clinical trials.